Taken together, these in vivo studies demonstrated that the combination of ICIs (a-PDL1 and a-CTLA4) with LDHIs (Oxa and NHI-2) enhances the efficacy of ICIs in a melanoma tumor model. This evidence concerns the gene CTLA4 and melanoma.